{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:04:50Z","timestamp":1789578290962,"version":"build-2803163510"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T00:00:00Z","timestamp":1651708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Hematol Blood Transfus"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1007\/s12288-022-01541-1","type":"journal-article","created":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T14:16:37Z","timestamp":1651760197000},"page":"141-145","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cytogenetic Risk Stratification of B-Acute Lymphoblastic Leukemia and Its Correlation with Other Prognostic Factors"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4368-4038","authenticated-orcid":false,"given":"Ritu","family":"Chadha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. S.","family":"Udayakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani","family":"Sangwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhawana","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalini","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Rastogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshan","family":"Dixit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. P.","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renu","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,5]]},"reference":[{"issue":"9","key":"1541_CR1","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/j.humpath.2012.02.004","volume":"43","author":"Y Zhou","year":"2012","unstructured":"Zhou Y, You MJ, Young KH, Lin P et al (2012) Advances in the molecular pathobiology of B-lymphoblastic leukemia. Hum Pathol 43(9):1347\u20131362","journal-title":"Hum Pathol"},{"issue":"9","key":"1541_CR2","doi-asserted-by":"publisher","first-page":"4477","DOI":"10.1182\/blood-2007-09-112920","volume":"111","author":"A M\u00f6ricke","year":"2008","unstructured":"M\u00f6ricke A, Reiter A, Zimmermann M et al (2008) Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 111(9):4477\u20134489","journal-title":"Blood"},{"key":"1541_CR3","unstructured":"NCCN Practice guidelines in oncology (2014) Acute lymphoblastic leukemia. Version 1. NCCN.org"},{"key":"1541_CR4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1056\/NEJMra052603","volume":"354","author":"C-H Pui","year":"2006","unstructured":"Pui C-H, Evans WE (2006) Treatment of acute lymphoblastic leukemia. N Engl J Med 354:166\u2013178","journal-title":"N Engl J Med"},{"issue":"5","key":"1541_CR5","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S1470-2045(10)70066-8","volume":"11","author":"AV Moorman","year":"2010","unstructured":"Moorman AV, Ensor HM, Richards SM et al (2010) Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97\/99 randomised trial. Lancet Oncol 11(5):429\u2013438","journal-title":"Lancet Oncol"},{"issue":"2","key":"1541_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.4103\/IJPM.IJPM_466_16","volume":"60","author":"N Patkar","year":"2017","unstructured":"Patkar N, Subramanian PG, Tembhare P et al (2017) An integrated genomic profile that includes copy number alterations is highly predictive of minimal residual disease status in childhood precursor B-lineage acute lymphoblastic leukemia. Indian J Pathol Microbiol 60(2):209\u2013213","journal-title":"Indian J Pathol Microbiol"},{"issue":"18","key":"1541_CR7","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1038\/sj.leu.2403001","volume":"17","author":"AV Borowitz MJ","year":"2003","unstructured":"Borowitz MJ, Pullen DJ, Shuster JJ, Viswanatha D, Montgomery K, Willman CL, Camitta B, Children\u2019s Oncology Group Study (2003) Minimal residual disease detection in childhood precursor-B-cell acute lymphoblastic leukemia: relation to other risk factors. A Children\u2019s Oncology Group study. Leukemia 17(8):1566\u20131572","journal-title":"Leukemia"},{"key":"1541_CR8","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1182\/blood.V96.8.2691","volume":"96","author":"E Coustan-Smith","year":"2000","unstructured":"Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC et al (2000) Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia. Blood 96:2691\u20132696","journal-title":"Blood"},{"key":"1541_CR9","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1182\/blood.V99.6.1952","volume":"99","author":"MN Dworzak","year":"2002","unstructured":"Dworzak MN, Froschl G, Printz D, Mann G, Potschger U, Muhlegger N et al (2002) Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 99:1952\u20131958","journal-title":"Blood"},{"key":"1541_CR10","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/S0140-6736(98)04058-6","volume":"352","author":"JJ van Dongen","year":"1998","unstructured":"van Dongen JJ, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L et al (1998) Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet 352:1731\u20131738","journal-title":"Lancet"},{"issue":"12","key":"1541_CR11","doi-asserted-by":"publisher","first-page":"5477","DOI":"10.1182\/blood-2008-01-132837","volume":"111","author":"MJ Borowitz","year":"2008","unstructured":"Borowitz MJ, Devidas M et al (2008) Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children\u2019s Oncology Group study. Blood 111(12):5477\u20135485","journal-title":"Blood"},{"issue":"3","key":"1541_CR12","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1182\/blood-2006-01-024729","volume":"109","author":"KR Schultz","year":"2007","unstructured":"Schultz KR, Pullen DJ, Sather HN et al (2007) Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children\u2019s Cancer Group (CCG). Blood 109(3):926\u2013935","journal-title":"Blood"}],"container-title":["Indian Journal of Hematology and Blood Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-022-01541-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12288-022-01541-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12288-022-01541-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,22]],"date-time":"2023-01-22T09:05:03Z","timestamp":1674378303000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12288-022-01541-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,5]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["1541"],"URL":"https:\/\/doi.org\/10.1007\/s12288-022-01541-1","relation":{},"ISSN":["0971-4502","0974-0449"],"issn-type":[{"value":"0971-4502","type":"print"},{"value":"0974-0449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,5]]},"assertion":[{"value":"24 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare no conflict of interest in writing this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical committee approval was taken.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}